News
BIOVF
32.06
NaN%
--
Sobi To Acquire Arthrosi Therapeutics
NASDAQ · 1d ago
Sobi Acquires Arthrosi Therapeutics to Strengthen Gout Treatment Pipeline
TipRanks · 3d ago
Sobi Announces CHMP's Positive Opinion For Aspaveli
NASDAQ · 4d ago
Swedish Orphan Biovitrum AB reports Q3 results
Seeking Alpha · 10/23 14:10
Sobi Q3 Adj. EBITA Rises
NASDAQ · 10/20 08:22
Sobi raises 2025 financial forecast after Q3 revenue jumps 21%
Seeking Alpha · 10/20 07:21
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs
Seeking Alpha · 09/19 13:36
Weekly Report: what happened at BIOVF last week (0908-0912)?
Weekly Report · 09/15 11:51
Weekly Report: what happened at BIOVF last week (0901-0905)?
Weekly Report · 09/08 11:53
Weekly Report: what happened at BIOVF last week (0825-0829)?
Weekly Report · 09/01 11:47
Weekly Report: what happened at BIOVF last week (0818-0822)?
Weekly Report · 08/25 12:01
Weekly Report: what happened at BIOVF last week (0811-0815)?
Weekly Report · 08/18 11:50
Weekly Report: what happened at BIOVF last week (0804-0808)?
Weekly Report · 08/11 12:00
Weekly Report: what happened at BIOVF last week (0728-0801)?
Weekly Report · 08/04 12:03
Weekly Report: what happened at BIOVF last week (0721-0725)?
Weekly Report · 07/28 12:03
Weekly Report: what happened at BIOVF last week (0714-0718)?
Weekly Report · 07/21 11:51
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook
Seeking Alpha · 07/16 06:46
Weekly Report: what happened at BIOVF last week (0707-0711)?
Weekly Report · 07/14 12:03
Weekly Report: what happened at BIOVF last week (0630-0704)?
Weekly Report · 07/07 11:52
Weekly Report: what happened at BIOVF last week (0623-0627)?
Weekly Report · 06/30 12:00
More
Webull provides a variety of real-time BIOVF stock news. You can receive the latest news about Swedish Orphan Biovitrum Ab through multiple platforms. This information may help you make smarter investment decisions.
About BIOVF
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.